It was also found that HCC patients showed significantly higher expression of FCN3 in serum after radiofrequency ablation, and this study suggests that FCN3 may be a biomarker for the therapeutic efficacy of radiofrequency ablation and a potential target for immunotherapy of HCC (Shen et al., 2018). This evidence concerns the gene FCN3 and hepatocellular carcinoma.